Comparative effects of CPAP and Mandibular Advancement Device Treatment on Cardiac Structure and Function in OSA: A Cardiovascular Magnetic Resonance Randomised Controlled Study

Short title: CRESCENT CMR Substudy

Nithin R. Iyer MBBS[1,2],* Yi-hui Ou BSc(Pharm)[3],* Jennifer A. Bryant PhD[2], Thu-Thao Le PhD[2,4], Juliana Tereza Colpani DDS MS[5], Crystal S. Cheong MBBS[6], Weiqiang Loke BDS[5], Peter A. Cistulli MBBS PhD[7,8], Martin Ugander MD PhD[1,9], Chi-hang Lee MBBS MD[3,10,11] and Calvin W-L. Chin MD PhD[2,4,12]

[1]Kolling Institute, Royal North Shore Hospital, and the University of Sydney, Sydney, Australia

[2]National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore

[3]Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

[4]Cardiovascular Sciences ACP, Duke NUS Medical School, Singapore

[5]Department of Endodontics, Operative Dentistry and Prosthodontics, Faculty of Dentistry, National University of Singapore, Singapore

[6]Department of Otolaryngology–Head & Neck Surgery, National University Hospital, Singapore, Singapore

[7]Sleep Research Group, Charles Perkins Centre and Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia

[8]Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia

[9]Department of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden

[10]Cardiovascular Research Institute, National University Heart Centre, Singapore, Singapore

[11]Department of Cardiology, National University Heart Centre, Singapore, Singapore

[12]Department of Cardiology, National Heart Centre Singapore, Singapore

*N.R. Iyer and Y-h. Ou contributed equally as first authors

Corresponding Author
A/Prof Calvin Chin
Department of Cardiology
5 Hospital Drive, Singapore 169609
Email: gmsccwl@nus.edu.sg
Phone: (65) 6704 8905
Fax: (65) 6844 9030

Abstract

Aims

Adverse cardiac remodelling is observed in obstructive sleep apnoea (OSA). However, the

impact of OSA treatment on cardiac remodelling remains poorly defined. The Cardiosleep

Research Program on Obstructive Sleep Apnoea, Blood Pressure Control and Maladaptive

Myocardial Remodeling—Non-inferiority Trial (CRESCENT) showed that treatment with a

mandibular advancement device (MAD) was non-inferior to continuous positive airway

pressure (CPAP) for reducing 24-hour mean arterial BP in patients with hypertension and

moderate-to-severe OSA. This cardiovascular magnetic resonance (CMR) substudy aimed to

evaluate the comparative effects of MAD and CPAP on myocardial structure and function in

patients with OSA.

Methods and Results

85 patients with hypertension, increased cardiovascular risk and newly-diagnosed moderate-

to-severe OSA (Apnoea-Hypopnoea Index [AHI] ≥15 events/hour), underwent contrast-

enhanced CMR at baseline and following 12 months of treatment with CPAP (n=49) or MAD

(n=36). LV mass, volumes, function and markers of diffuse myocardial fibrosis, including the

extracellular volume (ECV) fraction and interstitial volume, were measured. Across the

cohort, a small reduction in the ECV fraction was observed (25.0±2.0 vs 24.3±2.0%;

p=0.002), accompanied by a reduction in the interstitial volume over a 12-month period of

OSA treatment (24.0[21.3-27.7] vs 23.3[20.4-27.4]mL; p=0.044). The reduction in ECV

fraction was similar between the CPAP and MAD groups (p=0.94).

Conclusion

12 months treatment of OSA with either CPAP or MAD in patients with hypertension is associated with a small reduction in myocardial ECV fraction, a surrogate marker of diffuse myocardial fibrosis. Further confirmation of these findings in larger cohorts is warranted.

(Cardiosleep Research Program on Obstructive Sleep Apnea, Blood Pressure Control and Maladaptive Myocardial Remodeling—Non-inferiority Trial [CRESCENT]; NCT04119999).

Keywords

Cardiovascular magnetic resonance; Continuous Positive Airway Pressure; Occlusal Splints; Hypertension; Sleep Apnea, Obstructive

Non-standard Abbreviations and Acronyms

CMR: Cardiovascular magnetic resonance

CPAP: Continuous positive airway pressure

ECV: Myocardial extracellular volume fraction

LV: left ventricle

MAD: Mandibular advancement device

OSA: Obstructive sleep apnoea

Introduction

Obstructive sleep apnoea (OSA) is a highly prevalent condition that is thought to affect nearly

1 billion people worldwide [1]. Patients with OSA develop recurrent collapse of the pharyngeal

airway during sleep, resulting in intermittent hypoxaemia, sympathetic activation, and

exaggerated intrathoracic pressure swings [2]. These perturbations are associated with acute

and chronic haemodynamic effects, and particularly alterations in blood pressure [3, 4]. OSA is

associated with several cardiovascular complications, including hypertension, atrial fibrillation,

heart failure, coronary artery disease, stroke, pulmonary hypertension, metabolic syndrome,

diabetes and sudden cardiac death.

Adverse cardiac remodelling is often observed in OSA, including left ventricular (LV)

hypertrophy, left and right ventricular dysfunction, and focal myocardial fibrosis [5-7]. There is

emerging evidence that treatment of OSA with continuous positive airway pressure (CPAP),

the primary treatment for OSA, is associated with improvement in left ventricular function, in

addition to right ventricular systolic function [8-10]. Mandibular advancement devices (MAD)

treat OSA by advancing the mandible and are an effective alternative to CPAP, demonstrating

improvement in OSA symptoms and quality of life [11-13]. Few studies have assessed the

effect of MAD on ventricular structure and function in patients with OSA. One

echocardiographic study showed improvement in LV hypertrophy in patients with OSA treated

with MAD for six months [14]. Additionally, it is not known whether treatment of OSA, with

either MAD or CPAP, can reverse myocardial fibrosis.

Cardiovascular magnetic resonance (CMR) imaging has become the non-invasive reference

standard for interrogating the myocardium due to its ability to accurately assess cardiac

morphology, function, and myocardial tissue characteristics. In particular, late gadolinium

enhancement (LGE) permits visualisation of focal replacement myocardial fibrosis, while T1

mapping pre- and post-gadolinium contrast enables non-invasive measurement of the

myocardial extracellular volume (ECV) fraction, a quantitative marker of myocardial diffuse

interstitial fibrosis.

Recently, the CRESCENT randomised trial (Cardiosleep Research Program on Obstructive

Sleep Apnoea, Blood Pressure Control and Maladaptive Myocardial Remodeling—Non-

inferiority Trial) showed that MAD was non-inferior to CPAP for reducing 24-hour mean

arterial BP in patients with hypertension and moderate-to-severe OSA, after 6 months of

treatment [13]. The present study was a cardiac MRI substudy of the CRESCENT trial and was

designed to determine the effects of MAD and CPAP on myocardial structure and function,

including markers of myocardial fibrosis, in patients with moderate-to-severe OSA.

Methods

Study Population and Trial Design

The CRESCENT trial design has been described previously [13]. Briefly, this was a

randomized, controlled, non-inferiority trial conducted in Singapore (NCT04119999).

Participants were recruited from October 1, 2019, to December 5, 2022, through medical

record screening at three public hospitals in Singapore. Inclusion criteria consisted of adults

aged ≥40 years with known hypertension and at least one other factor for high cardiovascular

risk for screening polysomnography, including diabetes mellitus; stroke or transient

ischaemic attack; significant coronary artery disease (at least one stenosis of >50% in at least

one major epicardial artery on invasive or CT coronary angiography, previous coronary

revascularisation, previous myocardial infarction or abnormal stress test); chronic kidney

disease with an estimated glomerular filtration rate of less than 60mL/min/1.73m^2 or age of

75 years or older [13]. Exclusion criteria included known OSA on treatment; Cheyne-Stokes

breathing or predominantly central sleep apnoea; secondary hypertension; unsuitable

anatomy for MAD; life expectancy <1 year; hypertensive crisis, acute coronary syndromes,

or acute heart failure in the past 30 days.

Participants underwent polysomnography following recruitment, and completed the Epworth

Sleepiness Scale (ESS) questionnaire. OSA was diagnosed based on the apnoea-hypopnoea

index (AHI), quantified as the total number of apnoeas or hypopnoeas per hour of sleep.

Patients diagnosed with moderate-to-severe OSA (AHI ≥15 events per hour) were randomly

assigned to treatment by MAD or CPAP in a 1:1 ratio. The treatment duration was 12

months. Device adherence was determined in the MAD group by an embedded compliance

micro-recorder chip (DentiTrac, Braebon), and in the CPAP group by a cloud-based

telemedicine management platform (Airview, ResMed Corp). Device adherence was defined

as ≥4 hours usage per night, beyond which CPAP treatment may reduce the incidence of

cardiovascular events [15]. The Institutional Review Board approved the trial (The Domain

Specific Review Board-C: 2019/00359, approved on August 28, 2019). All participants

provided written informed consent.

Cardiovascular magnetic resonance image acquisition

All patients in the CRESCENT cohort were invited and assessed for suitability for CMR, up

to a pre-specified total of 100 patients. Those who agreed and were eligible underwent a

standardised CMR protocol with a Siemens Aera 1.5 Tesla MRI scanner (Siemens

Healthineers, Erlangen, Germany) at baseline and following 12 months of treatment with

MAD or CPAP. Balanced steady-state free-precession cines were acquired in the standard

long-axis views and a short-axis stack was acquired from base to apex. LGE images were

acquired at 10 min after 0.1 mmol/kg of gadobutrol (Gadovist®, Bayer Pharma AG,

Germany) with a phase-sensitive inversion-recovery gradient-echo imaging sequence. The

inversion time for optimal myocardial nulling was selected from an inversion time scout

sequence. T1 maps were acquired at the basal and mid-ventricular short-axis levels, pre- and

15-min post-contrast with modified Look-Locker inversion-recovery (MOLLI) 5s(3s)3s and

4s(1s)3s(1s)2s acquisition schemes, respectively.

CMR analysis

Image analysis was performed using CVI42 software (Circle Cardiovascular Imaging,

Calgary, Canada) by trained imaging fellows at the National Heart Research Institute of

Singapore CMR Core Laboratory, who were blinded to the patients' clinical status.

Ventricular volumes, mass and ejection fraction, were measured from the short-axis cine

stack, using manual contouring of the left ventricle in end-diastole and end-systole, excluding

papillary muscles, as detailed previously [16]. LV volumes and mass were indexed to body

surface area. The presence of LGE was assessed qualitatively by two readers according to the

recommendations by the Society of CMR [17]. Average native and post-contrast myocardial

T1 values were measured by placing a region of interest (ROI) within the middle third of the

short-axis myocardial wall at the basal- and mid-ventricular levels while avoiding areas of

focal LGE. The myocardium-blood pool interface was carefully avoided to prevent partial

volume effects. Pre- and post-contrast blood T1 values were measured in a ROI drawn within

the blood pool. The ECV fraction was calculated from the pre-and post-contrast average

blood and myocardial T1 values, as described previously [18, 19], and is reported as a mean

value from the basal and mid-ventricular slices. The myocardial interstitial volume was

calculated as: $\frac{ECV}{100} \times Myocardial\ volume$, where myocardial volume (mL) was defined as

myocardial mass (g)/1.05 g/mL. Myocyte volume was calculated as: $\left(1 - \frac{ECV}{100}\right) \times$

$Myocardial\ volume$. Myocardial strain was analysed in the cine images using the Tissue

Tracking Plugin (Circle Cardiovascular Imaging, Calgary, Canada).

Statistics

Normality for continuous variables was assessed using the Shapiro-Wilk test. Normally

distributed data are presented as mean ± standard deviation. Non-normally distributed data

are presented as median [interquartile range]. Comparisons were performed for continuous

variables before and after treatment using the parametric paired Student *t*-test or the non-

parametric Wilcoxon signed-ranked test. Pearson's correlation coefficient was used to assess

correlations between continuous variables. Categorical variables are presented as number

(percentage) and compared using the χ^2 test. Statistical analyses were performed using SPSS

Version 29 (Statistical Package for the Social Sciences, International Business Machines,

Inc., Armonk, New York, USA) and GraphPad Prism 9.4.1 (GraphPad Software, Inc., San

Diego, California, USA). A two-sided p-value <0.05 was considered as statistically

significant.

Results

Of the 220 participants in the CRESCENT study who were randomly allocated to either MAD

or CPAP in a 1:1 allocation, 101 patients agreed and were eligible to participate in the CMR

substudy. These patients underwent baseline CMR (Figure 1). Out of this group, 84.2% (85 of

101) underwent serial CMR at 12 months and were included in this sub-study (median age: 61

years; 91% [77 of 85] males; MAD: 36; CPAP: 49).

At baseline, the median BMI was 28 [26-31] kg/m^2. The baseline 24-hour mean arterial BP was

96±8 mmHg. Of the cardiovascular co-morbidities, 61% (52 of 85) had coronary artery disease,

and 60% (51 of 85) had diabetes mellitus. All patients had hypertension. OSA was classified as

severe in 68% (58 of 85) of patients. The baseline median AHI for the cohort was 41 [27-59]

events per hour. The ESS at baseline was 7.8 ± 4.3. The baseline CMR characteristics are given

in Table 1. Patients in the MAD group were older compared to the CPAP group (MAD: 64 [57-

69] years vs CPAP: 59 [53-64] years; p = 0.043). Otherwise, there were no clinical, sleep or

CMR differences in baseline characteristics between the MAD and CPAP groups

(Supplemental Table 1).

Valid adherence data at 12 months was available for 58% (21 of 36) in the MAD group. The

mean duration of device usage per night was 4.6±2.4 hours in this group. In the MAD group,

62% (13 of 21) used the device for ≥4 hours per night and were classified as adherent.

Adherence data was available for 92% (45 of 49) in the CPAP group. The mean duration of

device usage per night in this group was 4.3±2.0 hours, with 64% (29 of 45) being adherent.

The difference between groups in adherence was not statistically significant (p=0.57).

In the MAD group, the ECV fraction decreased from 24.9±2.3% at baseline to 24.0±2.2% at

month 12; p=0.042). The ECV fraction decreased in the CPAP group from 25.1±1.9% at

baseline to 24.5±1.8% at month 12 (p=0.016). Change in ECV fraction did not differ according

to treatment device (MAD: -0.6[-1.6-0.4] % vs CPAP: -0.6[-2.1-0.5] %; p=0.94). Amongst the

CMR markers in the entire cohort, there was a reduction in the ECV fraction (baseline:

25.0±2.0 vs month 12: 24.3±2.0%; p=0.002), with associated reduction in the interstitial

volume (24.0[21.3-27.7] vs 23.3[20.4-27.4] mL; p=0.044) (Figure 2). All other CMR

parameters in the entire cohort, including LV mass and LV myocyte volume, did not differ, and

these results were consistent across treatment groups (Table 2).

An exploratory analysis of clinical and CMR markers associated with ECV fraction change

showed a reduction in the ECV fraction in obese patients (baseline BMI ≥30kg/m^2; baseline

ECV: 25.2[23.9-26.6]% vs month 12 ECV: 23.9[22.5-25.3]%; n=25; p<0.001). Furthermore,

obese patients were more likely to experience a reduction in the ECV fraction (change in obese:

-1.2[-1.9 to -0.3]% vs change in non-obese: -0.4[-1.6 to 0.8]%; p=0.026) (Figure 3). Obese

patients had a higher AHI at baseline (54[42-69] events per hour vs 32[23-48] events per hour;

p<0.001), and experienced a greater reduction in AHI with treatment (58[42-66] events per

hour vs 31[23-46] events per hour; p=0.001).

Otherwise, there were no associations detected between ECV fraction change and change in

clinical, sleep or other CMR markers (Supplemental Table 2).

Discussion

To our knowledge, this is the first CMR study to assess the comparative effects of MAD and

CPAP therapy for OSA on longitudinal change in cardiac functional parameters. The main

finding in this study was that treatment of OSA, with either MAD or CPAP, was associated

with a small reduction in the ECV fraction, a surrogate marker of diffuse myocardial fibrosis.

Conversely, no change was observed in LV mass or function.

OSA is thought to mediate myocardial fibrosis via several mechanisms. Chronic intermittent

hypoxia, a hallmark of OSA, has been shown to induce cardiac inflammation, apoptosis and

fibrosis in rats [20]. Heightened sympathetic drive due to recurrent apnoeas during sleep has

been implicated in the development of cardiac interstitial fibrosis in animal models [21, 22].

Resting awake OSA patients have increased BP variability, which has been shown to induce

myocardial fibrosis in hypertensive rats [22-24]. Alternating cycles of hypoxaemia and

reoxygenation may trigger oxidative stress mechanisms, which are known to be involved in the

development of myocardial fibrosis [22, 25]. Finally, hypertension, commonly found in

patients with OSA, is known to cause both replacement and diffuse myocardial fibrosis [26,

27].

Treatment of OSA is known to target a number of pathways that have been linked to the

development of myocardial fibrosis. The evidence is strongest for CPAP. In particular, CPAP

has been shown to reduce sympathetic drive and acutely decrease BP during sleep [28, 29]. The

chronic effects of CPAP on BP are more modest, with greater benefit evident in hypertensive

rather than normotensive patients [30]. CPAP reduces nocturnal, in addition to waking, BP

variability [31, 32]. Markers of oxidative stress are reduced with CPAP therapy [33, 34]. CPAP

has also been shown to improve nocturnal hypoxemia [35]. Therefore, it is plausible that CPAP

may reduce myocardial fibrosis in OSA through these mechanisms.

Myocardial fibrosis includes both replacement fibrosis and reactive interstitial fibrosis.

Replacement fibrosis, represented by late gadolinium enhancement in CMR imaging,

corresponds to the replacement of myocytes with collagen following myocyte necrosis and is

thought to be irreversible [36]. Reactive interstitial fibrosis, measured with T1 mapping and

ECV fraction at CMR, is characterised by collagen deposition by myofibroblasts within the

interstitium and perivascular space. It is considered a marker of intermediate disease severity

and potentially reversible [37, 38]. The observed reduction in the ECV fraction, along with a

reduction in the absolute myocardial interstitial volume, indicates that treatment of OSA with

MAD or CPAP may specifically reduce the burden of myocardial fibrosis through effects on

the interstitium. However, it must be noted that most patients in this cohort had normal ECV

fraction values at baseline [39] and the absolute reduction in ECV fraction was small, within

the expected measurement variability. Therefore, the observed change in ECV fraction is

unlikely to be clinically significant in this cohort. Future work should evaluate whether a cohort

with more advanced OSA (with poorer control of hypertension, higher rates of obesity and/or

heart failure with preserved ejection fraction), and therefore with higher expected baseline

myocardial fibrosis [40-42], might derive more clinically meaningful improvement in ECV

fraction with OSA treatment.

Myocardial fibrosis regression has been documented previously following interventions in other cardiac diseases, including aortic valve replacement for aortic stenosis and pirfenidone, an oral antifibrotic agent, for heart failure with preserved ejection fraction [38, 43]. Both studies observed changes in ECV fraction and interstitial volume after one year of treatment. The magnitude of ECV fraction reduction was higher with pirfenidone (-1.21% compared to placebo) compared to this study. This likely reflects the more advanced heart failure population in that study, with baseline mean myocardial ECV fraction measuring 30.1%. ECV fraction was paradoxically increased following aortic valve replacement for aortic stenosis due to greater effects on the myocyte compartment.

The reduction in ECV fraction was noted across both MAD and CPAP groups. A growing body of evidence suggests that MAD may have similar cardiovascular benefits to CPAP. MAD has been shown to improve nocturnal hypoxaemia [44]. MAD has a similar BP-lowering effect compared to CPAP [13]. There is emerging evidence to suggest that MAD treatment can improve cardiac autonomic function [45]. Based on these benefits, it is plausible that MAD therapy would also be able to reduce myocardial fibrosis. This is an important finding, since MADs are often preferred by patients with OSA compared to CPAP [46], indicating great potential to improve cardiovascular health.

In this study, there was no difference observed in left ventricular mass, atrial and ventricular volumes, and ventricular function following treatment for OSA. Prior to this study, a few longitudinal CMR studies have assessed for change in cardiac functional parameters following initiation of CPAP in OSA. Results have been mixed. One study showed reduction in indexed

right and left atrial volumes, indexed RV end diastolic volume, and indexed left ventricular mass at 1 year following initiation of CPAP therapy [8]. Notably, the cohort in that study at baseline was generally heavier (mean BMI 38 kg/m^2), more symptomatic (mean ESS 14) and had more severe OSA (mean AHI 63 events/hour), which may have explained the discrepancy in findings compared to our study. Two studies have shown improvement in RV volumes or RV ejection fraction with CPAP therapy [9, 47]. In both studies, patients had a higher BMI at baseline (33-35 kg/m^2) compared to our study (28 kg/m^2). Another study showed no change in CMR parameters after four months of CPAP therapy in non-obese and obese CPAP-naïve patients [48]. The patients included were most similar to our cohort based on baseline symptoms (mean ESS 9.5), BMI (31.6 kg/m^2) and severity of OSA (mean AHI 36 events/hour), which may have explained the similarity in findings.

The finding of a change in myocardial fibrosis markers without associated changes in cardiac mass, volumes or function has precedent. Recently, pirfenidone was found to reduce the ECV fraction in patients with heart failure without any effects on cardiac functional parameters or LV mass [38]. This is an antifibrotic agent without haemodynamic effect and is therefore thought to target the extracellular matrix. In an earlier study, lisinopril caused regression of myocardial fibrosis in patients with hypertensive heart disease, as measured with the LV collagen fraction and myocardial hydroxyproline concentration from endomyocardial biopsy, without any effects on LV hypertrophy [49]. These results were in keeping with the perception that haemodynamics are the most relevant determinants of LVH. Since the BP was controlled at baseline, no changes in LVH were detected [49]. Similarly, the patients in our study had well-controlled BP at baseline, which may have explained why no regression in LV mass was observed.

Limitations

Our study has a few limitations. First, this was an exploratory analysis in a CMR substudy of the CRESCENT trial. The hypothesis that OSA treatment would reduce the myocardial ECV fraction was not *a priori*. Second, this was a single-centre CMR study. Although the sample size was small, this was similar to previous CMR studies assessing the longitudinal effect of OSA treatment on cardiac functional parameters. Third, the participants were all of Chinese ethnicity and mostly male (91%), which may limit the generalisability [13].

Conclusion

Treatment of moderate-to-severe OSA, with either MAD or CPAP, in patients with hypertension and high cardiovascular risk, is associated with a small reduction in myocardial ECV fraction, a surrogate marker of diffuse myocardial fibrosis, at 12 months, with an associated reduction in the myocardial interstitial volume.

Sources of Funding

This study was supported by a Clinician Scientist Award from the National Medical Research Council of Singapore (Grant number: CSASI18may-0001) and the USyd-NUS Partnership

Collaboration Award, a joint award from the National University of Singapore and the

University of Sydney.

Data Availability Statement

The datasets generated and analysed for the current study are not publicly available. Please

contact the corresponding author for data requests.

Disclosures

Dr Cistulli has an appointment as an endowed Academic Chair at the University of Sydney

that was created from ResMed funding (he receives no personal fees, and this relationship is

managed by an Oversight Committee of the University); has received research support from

ResMed, SomnoMed, Zephyr Sleep Technologies, and Bayer; is a consultant/adviser to

Signifier Medical Technologies, SomnoMed, ResMed, and Sunrise Medical; and has a

pecuniary interest in SomnoMed related to a previous role in R&D (2004). Dr Ugander is

principal investigator for an institutional research and development agreement regarding

cardiovascular magnetic resonance imaging between Karolinska University Hospital and

Siemens. Dr Lee has received an honorarium from ResMed (2022); and has received a

research grant from Boston Scientific Corporation. All other authors have reported that they

have no relationships relevant to the contents of this paper to disclose.

References

1.   Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-98. Epub 2019/07/14. doi: 10.1016/S2213-2600(19)30198-5. PubMed PMID: 31300334; PubMed Central PMCID: PMCPMC7007763.

2.   Levy P, Kohler M, McNicholas WT, Barbe F, McEvoy RD, Somers VK, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015;1:15015. Epub 2015/01/01. doi: 10.1038/nrdp.2015.15. PubMed PMID: 27188535.

3.   Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008;5(2):144-53. Epub 2008/02/06. doi: 10.1513/pats.200707-114MG. PubMed PMID: 18250206; PubMed Central PMCID: PMCPMC2628457.

4.   Baguet JP, Barone-Rochette G, Tamisier R, Levy P, Pepin JL. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol. 2012;9(12):679-88. Epub 2012/09/26. doi: 10.1038/nrcardio.2012.141. PubMed PMID: 23007221.

5.   Cloward TV, Walker JM, Farney RJ, Anderson JL. Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. Chest. 2003;124(2):594-601. Epub 2003/08/09. doi: 10.1378/chest.124.2.594. PubMed PMID: 12907548.

6.   Laaban JP, Pascal-Sebaoun S, Bloch E, Orvoen-Frija E, Oppert JM, Huchon G. Left ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome. Chest. 2002;122(4):1133-8. Epub 2002/10/16. doi: 10.1378/chest.122.4.1133. PubMed PMID: 12377833.

7.   Shah NA, Reid M, Kizer JR, Sharma RK, Shah RV, Kundel V, et al. Sleep-disordered breathing and left ventricular scar on cardiac magnetic resonance: results of the Multi-Ethnic Study of Atherosclerosis. J Clin Sleep Med. 2020;16(6):855-62. Epub 2020/02/08. doi: 10.5664/jcsm.8340. PubMed PMID: 32029066; PubMed Central PMCID: PMCPMC7849673.

8.   Colish J, Walker JR, Elmayergi N, Almutairi S, Alharbi F, Lytwyn M, et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest. 2012;141(3):674-81. Epub 2011/08/13. doi: 10.1378/chest.11-0615. PubMed PMID: 21835901.

9.   Wuest W, May MS, Wiesmueller M, Uder M, Schmid A. Effect of long term CPAP therapy on cardiac parameters assessed with cardiac MRI. Int J Cardiovasc Imaging. 2021;37(2):613-21. Epub 2020/09/15. doi: 10.1007/s10554-020-02024-y. PubMed PMID: 32926309; PubMed Central PMCID: PMCPMC8423704.

10.   Sun H, Shi J, Li M, Chen X. Impact of continuous positive airway pressure treatment on left ventricular ejection fraction in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(5):e62298. Epub 2013/05/08. doi: 10.1371/journal.pone.0062298. PubMed PMID: 23650511; PubMed Central PMCID: PMCPMC3641077.

11.   Almeida FR, Henrich N, Marra C, Lynd LD, Lowe AA, Tsuda H, et al. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. Sleep Breath. 2013;17(2):659-66. Epub 2012/07/27. doi: 10.1007/s11325-012-0739-6. PubMed PMID: 22833346.

12.   Trzepizur W, Cistulli PA, Glos M, Vielle B, Sutherland K, Wijkstra PJ, et al. Health
outcomes of continuous positive airway pressure versus mandibular advancement device
for the treatment of severe obstructive sleep apnea: an individual participant data meta-
analysis. Sleep. 2021;44(7). Epub 2021/01/26. doi: 10.1093/sleep/zsab015. PubMed PMID:
33493338.
13.   Ou YH, Colpani JT, Cheong CS, Loke W, Thant AT, Shih EC, et al. Mandibular
Advancement vs CPAP for Blood Pressure Reduction in Patients With Obstructive Sleep
Apnea. J Am Coll Cardiol. 2024;83(18):1760-72. Epub 2024/04/09. doi:
10.1016/j.jacc.2024.03.359. PubMed PMID: 38588926.
14.   Dieltjens M, Vanderveken OM, Shivalkar B, Van Haesendonck G, Kastoer C,
Heidbuchel H, et al. Mandibular advancement device treatment and reverse left ventricular
hypertrophic remodeling in patients with obstructive sleep apnea. J Clin Sleep Med.
2022;18(3):903-9. Epub 2021/11/04. doi: 10.5664/jcsm.9766. PubMed PMID: 34728052;
PubMed Central PMCID: PMCPMC8883081.
15.   Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M, Carmona C,
Barcelo A, et al. Effect of continuous positive airway pressure on the incidence of
hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea:
a randomized controlled trial. JAMA. 2012;307(20):2161-8. Epub 2012/05/24. doi:
10.1001/jama.2012.4366. PubMed PMID: 22618923.
16.   Le TT, Tan RS, De Deyn M, Goh EP, Han Y, Leong BR, et al. Cardiovascular magnetic
resonance reference ranges for the heart and aorta in Chinese at 3T. J Cardiovasc Magn
Reson. 2016;18:21. Epub 2016/04/14. doi: 10.1186/s12968-016-0236-3. PubMed PMID:
27071974; PubMed Central PMCID: PMCPMC4830061.
17.   Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al.
Standardized image interpretation and post processing in cardiovascular magnetic
resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task
force on standardized post processing. J Cardiovasc Magn Reson. 2013;15(1):35. Epub
2013/05/03. doi: 10.1186/1532-429X-15-35. PubMed PMID: 23634753; PubMed Central
PMCID: PMCPMC3695769.
18.   Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, et al. Extracellular
volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical
myocardial pathology. Eur Heart J. 2012;33(10):1268-78. Epub 2012/01/27. doi:
10.1093/eurheartj/ehr481. PubMed PMID: 22279111; PubMed Central PMCID:
PMCPMC3350985.
19.   Arheden H, Saeed M, Higgins CB, Gao DW, Bremerich J, Wyttenbach R, et al.
Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR
imaging to quantify myocardial infarction: comparison with 99mTc-DTPA autoradiography in
rats. Radiology. 1999;211(3):698-708. Epub 1999/06/03. doi:
10.1148/radiology.211.3.r99jn41698. PubMed PMID: 10352594.
20.   Wei Q, Bian Y, Yu F, Zhang Q, Zhang G, Li Y, et al. Chronic intermittent hypoxia
induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model. J
Biomed Res. 2016;30(6):490-5. Epub 2016/12/08. doi: 10.7555/JBR.30.20160110. PubMed
PMID: 27924067; PubMed Central PMCID: PMCPMC5138581.
21.   Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, et al. Sympathectomy
or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload
hypertrophy. Hypertension. 2005;46(5):1213-8. Epub 2005/10/12. doi:
10.1161/01.HYP.0000185689.65045.4c. PubMed PMID: 16216989.

22.   Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea
and cardiovascular disease: an American Heart Association/american College Of Cardiology
Foundation Scientific Statement from the American Heart Association Council for High Blood
Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke
Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart,
Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes
of Health). Circulation. 2008;118(10):1080-111. Epub 2008/08/30. doi:
10.1161/CIRCULATIONAHA.107.189375. PubMed PMID: 18725495.
23.   Narkiewicz K, Montano N, Cogliati C, van de Borne PJ, Dyken ME, Somers VK. Altered
cardiovascular variability in obstructive sleep apnea. Circulation. 1998;98(11):1071-7. Epub
1998/09/16. doi: 10.1161/01.cir.98.11.1071. PubMed PMID: 9736593.
24.   Yasuoka S, Kai H, Kajimoto H, Kudo H, Takayama N, Anegawa T, et al. Blood pressure
variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in
hypertensive rats. Circ J. 2013;77(6):1474-81. Epub 2013/03/09. doi: 10.1253/circj.cj-12-
1253. PubMed PMID: 23470864.
25.   Dhalla NS, Elimban V, Bartekova M, Adameova A. Involvement of Oxidative Stress in
the Development of Subcellular Defects and Heart Disease. Biomedicines. 2022;10(2). Epub
2022/02/26. doi: 10.3390/biomedicines10020393. PubMed PMID: 35203602; PubMed
Central PMCID: PMCPMC8962363.
26.   Gonzalez A, Lopez B, Ravassa S, San Jose G, Latasa I, Butler J, et al. Myocardial
Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical
Management. Hypertension. 2024;81(2):218-28. Epub 2023/12/12. doi:
10.1161/HYPERTENSIONAHA.123.21708. PubMed PMID: 38084597.
27.   Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich).
2007;9(7):546-50. Epub 2007/07/10. doi: 10.1111/j.1524-6175.2007.06626.x. PubMed
PMID: 17617765; PubMed Central PMCID: PMCPMC8110048.
28.   Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity
after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J.
1995;8(2):222-9. Epub 1995/02/01. doi: 10.1183/09031936.95.08020222. PubMed PMID:
7758555.
29.   Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in
obstructive sleep apnea. J Clin Invest. 1995;96(4):1897-904. Epub 1995/10/01. doi:
10.1172/JCI118235. PubMed PMID: 7560081; PubMed Central PMCID: PMCPMC185826.
30.   Engleman HM, Asgari-Jirhandeh N, McLeod AL, Ramsay CF, Deary IJ, Douglas NJ. Self-
reported use of CPAP and benefits of CPAP therapy: a patient survey. Chest.
1996;109(6):1470-6. Epub 1996/06/01. doi: 10.1378/chest.109.6.1470. PubMed PMID:
8769496.
31.   Marrone O, Bonsignore MR. Blood-pressure variability in patients with obstructive
sleep apnea: current perspectives. Nat Sci Sleep. 2018;10:229-42. Epub 2018/09/04. doi:
10.2147/NSS.S148543. PubMed PMID: 30174467; PubMed Central PMCID:
PMCPMC6109653.
32.   Ali NJ, Davies RJ, Fleetham JA, Stradling JR. The acute effects of continuous positive
airway pressure and oxygen administration on blood pressure during obstructive sleep
apnea. Chest. 1992;101(6):1526-32. Epub 1992/06/01. doi: 10.1378/chest.101.6.1526.
PubMed PMID: 1600769.
33.   Eisele HJ, Markart P, Schulz R. Obstructive Sleep Apnea, Oxidative Stress, and
Cardiovascular Disease: Evidence from Human Studies. Oxid Med Cell Longev.

2015;2015:608438. Epub 2015/07/15. doi: 10.1155/2015/608438. PubMed PMID:
26167241; PubMed Central PMCID: PMCPMC4475750.
34. Stanek A, Brozyna-Tkaczyk K, Myslinski W. Oxidative Stress Markers among
Obstructive Sleep Apnea Patients. Oxid Med Cell Longev. 2021;2021:9681595. Epub
2021/08/03. doi: 10.1155/2021/9681595. PubMed PMID: 34336121; PubMed Central
PMCID: PMCPMC8321764.
35. Giles TL, Lasserson TJ, Smith B, White J, Wright JJ, Cates CJ. Continuous positive
airways pressure for obstructive sleep apnoea in adults. Cochrane Database of Systematic
Reviews. 2006;(3). doi: 10.1002/14651858.CD001106.pub3. PubMed PMID: CD001106.
36. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis
with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891-903. Epub
2011/02/19. doi: 10.1016/j.jacc.2010.11.013. PubMed PMID: 21329834; PubMed Central
PMCID: PMCPMC3081658.
37. Lewis GA, Dodd S, Naish JH, Selvanayagam JB, Dweck MR, Miller CA. Considerations
for Clinical Trials Targeting the Myocardial Interstitium. JACC Cardiovasc Imaging.
2019;12(11 Pt 2):2319-31. Epub 2019/08/20. doi: 10.1016/j.jcmg.2019.03.034. PubMed
PMID: 31422145.
38. Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, et al. Pirfenidone in
heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med.
2021;27(8):1477-82. Epub 2021/08/14. doi: 10.1038/s41591-021-01452-0. PubMed PMID:
34385704.
39. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1
Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J
Cardiovasc Magn Reson. 2016;18(1):89. Epub 2016/12/03. doi: 10.1186/s12968-016-0308-4.
PubMed PMID: 27899132; PubMed Central PMCID: PMCPMC5129251.
40. Yeo TM, Chin WLC, Seah CWA, Cheng LJ, Lin W, Dalakoti M, et al. Global Prevalence
of Myocardial Fibrosis among Individuals with Cardiometabolic Conditions: A Systematic
Review and Meta-Analysis. Eur J Prev Cardiol. 2025. Epub 2025/02/19. doi:
10.1093/eurjpc/zwaf083. PubMed PMID: 39968765.
41. Kuruvilla S, Janardhanan R, Antkowiak P, Keeley EC, Adenaw N, Brooks J, et al.
Increased extracellular volume and altered mechanics are associated with LVH in
hypertensive heart disease, not hypertension alone. JACC Cardiovasc Imaging.
2015;8(2):172-80. Epub 2015/01/13. doi: 10.1016/j.jcmg.2014.09.020. PubMed PMID:
25577446; PubMed Central PMCID: PMCPMC4418794.
42. Rommel KP, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K, et al.
Extracellular Volume Fraction for Characterization of Patients With Heart Failure and
Preserved Ejection Fraction. J Am Coll Cardiol. 2016;67(15):1815-25. Epub 2016/04/16. doi:
10.1016/j.jacc.2016.02.018. PubMed PMID: 27081022.
43. Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuva AN, et al. Reverse
Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. J Am
Coll Cardiol. 2018;71(8):860-71. Epub 2018/02/24. doi: 10.1016/j.jacc.2017.12.035. PubMed
PMID: 29471937; PubMed Central PMCID: PMCPMC5821681.
44. Park P, Jeon HW, Han DH, Won TB, Kim DY, Rhee CS, et al. Therapeutic outcomes of
mandibular advancement devices as an initial treatment modality for obstructive sleep
apnea. Medicine (Baltimore). 2016;95(46):e5265. Epub 2016/11/20. doi:
10.1097/MD.0000000000005265. PubMed PMID: 27861349; PubMed Central PMCID:
PMCPMC5120906 indicated no financial conflicts of interest.

45.	Ucak S, Dissanayake HU, Sutherland K, Bin YS, de Chazal P, Cistulli PA. Effect of mandibular advancement splint therapy on cardiac autonomic function in obstructive sleep apnoea. Sleep Breath. 2024;28(1):349-57. Epub 2023/09/29. doi: 10.1007/s11325-023-02924-y. PubMed PMID: 37770793; PubMed Central PMCID: PMCPMC10955011.

46.	Gagnadoux F, Fleury B, Vielle B, Petelle B, Meslier N, N'Guyen XL, et al. Titrated mandibular advancement versus positive airway pressure for sleep apnoea. Eur Respir J. 2009;34(4):914-20. Epub 2009/03/28. doi: 10.1183/09031936.00148208. PubMed PMID: 19324954.

47.	Magalang UJ, Richards K, McCarthy B, Fathala A, Khan M, Parinandi N, et al. Continuous positive airway pressure therapy reduces right ventricular volume in patients with obstructive sleep apnea: a cardiovascular magnetic resonance study. J Clin Sleep Med. 2009;5(2):110-4. Epub 2009/12/09. PubMed PMID: 19968042; PubMed Central PMCID: PMCPMC2670328.

48.	Xu L, Keenan BT, Maislin D, Gislason T, Benediktsdottir B, Gudmundsdottir S, et al. Effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling as Assessed by Cardiac Biomarker and Magnetic Resonance Imaging in Nonobese and Obese Adults. Hypertension. 2021;77(3):980-92. Epub 2021/01/20. doi: 10.1161/HYPERTENSIONAHA.120.15882. PubMed PMID: 33461313; PubMed Central PMCID: PMCPMC7878363.

49.	Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102(12):1388-93. Epub 2000/09/20. doi: 10.1161/01.cir.102.12.1388. PubMed PMID: 10993857.

Table 1. Clinical, sleep and CMR characteristics of the cohort at baseline and following 12 months of OSA treatment

	Baseline (n=85)	Follow-up (n=85)	p Value
Clinical			
Age, years	61 [54-66]		
Male sex, n (%)	77 (91)		
24-hour, mmHg			
Mean BP	96 ± 8		
Systolic BP	126 ± 11		
Diastolic BP	80 ± 8		
Body mass index, kg/m^2	27.8 [25.6-30.5]	28.8 [25.5-30.7]	0.04
Body surface area, m^2	1.92 [1.78-2.03]	1.91 [1.78-2.03]	0.80
Co-morbidities, n (%)			
Coronary artery disease	52 (61)		
Diabetes Mellitus	51 (60)		
Smoker	3 (4)		
Medications, n (%)			
Beta Blocker	47 (55)		
ACEi or ARB	72 (85)		
CCB	33 (39)		
Diuretic	12 (14)		
Statin	73 (86)		
Sleep			
AHI, events per hour	41 [27-59]	2 [1-4]*	<0.001
Patients with AHI			
<15 events per hour	0 (0)	45 (98)*	
15 to <30 events per hour	27 (32)	0 (0)*	
≥30 events per hour	58 (68)	1 (2)*	<0.001
Epworth sleepiness scale	7.8 ± 4.3		
CMR Markers			
LVEDV, mL	146 ± 39	148 ± 39	0.45
LVESV, mL	66 ± 31	67 ± 32	0.58
LVSV, mL	80 ± 18	81 ± 15	0.66
LV mass, g	102 [90-120]	103 [88-119]	0.72
LV ejection fraction, %	56 ± 9	56 ± 9	0.91
GLS, %	-15.0 ± 2.9	-15.5 ± 2.8	0.76
RVEDV, mL	145 ± 34	145 ± 30	0.72

RVESV, mL	64 ± 22	64 ± 20	0.98
RVSV, mL	80 ± 18	81 ± 15	0.58
RV ejection fraction, %	56 ± 8	56 ± 7	0.77
RA area, m^2	21 [18-24]	21 [18-23]	0.28
LA volume, mL	85 [68-101]	84 [71-101]	0.85
LGE Type			
Nil, n (%)	40 (47)		
Non-ischaemic, n (%)	12 (14)		
Ischaemic, n (%)	32 (38)		
Both, n (%)	1 (1)		
ECV fraction, %	25.0 ± 2.0	24.3 ± 2.0	0.002
Interstitial volume, mL	24.0 [21.3-27.7]	23.3 [20.4-27.4]	0.044
Myocyte volume, mL	72.9 [64.3-86.4]	73.4 [63.8-85.5]	0.52

Values are given as median [interquartile range], mean ± SD or number (percentage).

Abbreviations:; ACEi: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; CCB: Calcium channel blocker; AHI: Apnoea-hypopnoea index; LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVSV: Left ventricular stroke volume; GLS: Global longitudinal strain; RVEDV: Right ventricular end-diastolic volume; RVESV: Right ventricular end-systolic volume; RVSV: Right ventricular stroke volume; RA: Right atrial; LA: Left atrial; LGE: Late gadolinium enhancement; ECV: Extracellular volume.

*Follow-up data only available for CPAP group

Table 2. Change in CMR characteristics of the cohort following 12 months of treatment for OSA according to treatment group.

	MAD (n=36)	CPAP (n=49)	p Value
Change in CMR Markers			
LVEDV, mL	0.5 [-11.8 to 8.3]	2.0 [-3.0 to 8.0]	0.31
LVESV, mL	3.0 [-8.0 to 8.8]	2.0 [-7.5 to 8.0]	0.98
LVSV, mL	-1.5 [-5.8 to 7.0]	2.0 [-5.0 to 9.0]	0.17
LV mass, g	-0.8 [-5.3-3.8]	-0.1 [-3.7-4.9]	0.47
LV ejection fraction, %	-0.8 ± 5.9	0.7 ± 7.1	0.32
GLS, %	0.2 ± 1.7	-0.1 ± 2.5	0.54
RVEDV, mL	0.0 [-8.0 to 7.0]	2.0 [-3.0 to 8.5]	0.24
RVESV, mL	0.3 ± 13.4	-0.2 ± 9.9	0.86
RVSV, mL	-2.0 ± 13.0	2.6 ± 9.0	0.06
RV ejection fraction, %	-0.9 ± 6.1	0.9 ± 5.5	0.18
RA area, m^2	0 [-2 to 1]	-1 [-2 to 1]	0.75
LA volume, mL	-1.7 [-14.9 to 12.5]	3.4 [-7.0 to 13.4]	0.41
ECV fraction, %	-0.6 [-1.6 to 0.4]	-0.6 [-2.1 to 0.5]	0.94
Interstitial volume, mL	-0.6 [-2.1 to 1.1]	-0.5 [-1.8 to 1.2]	0.57
Myocyte volume, mL	0.3 [-5.1 to 2.9]	0.7 [-2.2 to 3.8]	0.47

Values are given as median [interquartile range] or mean ± SD.

Abbreviations: LVEDV: Left ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume; LVSV: Left ventricular stroke volume; GLS: Global longitudinal strain; RVEDV: Right ventricular end-diastolic volume; RVESV: Right ventricular end-systolic volume; RVSV: Right ventricular stroke volume; RA: Right atrial; LA: Left atrial; ECV: Extracellular volume.

Figure Titles and Legends

Figure 1. Flow chart of patient inclusion. Abbreviations: OSA: Obstructive sleep apnoea;

PSG: polysomnography; MAD: Mandibular advancement device; CPAP: Continuous

positive airways pressure; CMR: Cardiovascular magnetic resonance.

Figure 2. Extracellular volume fraction (ECV) fraction before and after OSA treatment.

ECV fraction (panel A) and absolute myocardial interstitial volume (panel C) were reduced

following 12 months of treatment for OSA. Left ventricular mass (panel B) and myocyte

volume (panel D) did not change following treatment. Whiskers were plotted using the Tukey

method.

Figure 3. Forest plot for subgroup analyses of treatment effect. Patients with obesity

(BMI $\geq 30 \text{kg/m}^2$) were more likely to experience a reduction in ECV fraction with OSA

treatment. Median and interquartile range are shown for all subgroup analyses. Dotted line

shows no effect point. Abbreviations: BMI: Body mass index; SBP: Systolic blood pressure;

AHI: Apnoea-hypopnoea index; ACEi: Angiotensin-converting enzyme inhibitor; ARB:

Angiotensin II receptor blocker.

Effect of mandibular advancement device therapy vs. continuous positive airway pressure on extracellular volume fraction

Patients with hypertension and newly diagnosed moderate-to-severe obstructive sleep apnoea (n=85)

Mandibular advancement device therapy (n=36)

Continuous positive airway pressure (n=49)

Myocardial changes at 12 months

↓ 0.6%

Change in myocardial extracellular volume fraction
(Between group comparison, p=0.94)

↓ 0.6%

Iyer *et al.* June 2025.